Bio-Techne amends Merck merger proxy as shareholder litigation targets vote

Bio-Techne is a life-science tools company spanning Protein Sciences and Diagnostics and Spatial Biology, now under contract to be acquired by Merck KGaA for $73 per share in cash. The filing adds execution risk, not a new operating development. One shareholder lawsuit seeks to stop or delay the September 23 vote, while multiple demand letters challenge the proxy’s disclosures. The company calls the claims meritless but cannot estimate any potential loss or outcome. 〔0〕

The supplemental disclosures make the deal process more transparent without changing the deal economics. They reveal that Merck previously expressed interest at $92-$95 per share in 2023, but those discussions did not progress into a transaction. That history may intensify shareholder scrutiny, but it is too old to represent a live competing offer or a changed bid.

The banker materials are mixed rather than decisively adverse to the transaction. The newly restated valuation analyses bracket the $73 offer unevenly: one range reaches $74, another stops at $72, and the EBITDA-based range tops out at $67. The disclosures therefore give shareholders more valuation context, but they do not establish that the agreed price falls outside Goldman Sachs’ broader analytical ranges.

The practical near-term issue is closing certainty. Bio-Techne is supplementing the proxy specifically to avoid the risk that the litigation could delay or adversely affect the merger, while leaving the September 23 meeting in place. 〔1〕

Bottom line: This is a process complication, not a revised merger proposal or a change in Bio-Techne’s business outlook. The added disclosures improve transparency, but the lawsuit and demands modestly increase uncertainty around the shareholder vote and closing timeline.